Cardiovascular Diseases, Cardiovascular Risk Factor, SARS
Conditions
Brief summary
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.
Interventions
DIAGNOSTIC_TESTAssessment of cardiovascular diseases and cardiovascular risk factors
At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
Sponsors
University Hospital, Essen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with suspected SARS-CoV2/Covid-19 infection
Exclusion criteria
* Unwillingness to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | During 1 year follow-up | mortality of any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 30-day mortality | Within 30 days after inclusion | mortality of any cause |
| Major adverse cardiovascular events | During 1 year follow-up | Myocardial infarction, stroke, or CV death |
Countries
Germany
Outcome results
None listed